Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Multicenter study of the efficacy, safety, tolerability, and pharmacokinetics of PlasmaCap IG in adults and children with primary immune deficiency disease met all primary and secondary endpoints.
Lead Product(s): Human Immunoglobulin
Therapeutic Area: Immunology Product Name: PlasmaCap IG
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2021